Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $40.05 Consensus Target Price from Analysts

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have received an average rating of “Moderate Buy” from the twenty-one ratings firms that are currently covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $40.05.

Several equities analysts have recently commented on APLS shares. Raymond James lowered Apellis Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the company from $75.00 to $52.00 in a research report on Friday, May 9th. Citigroup reduced their price objective on Apellis Pharmaceuticals from $49.00 to $41.00 and set a “buy” rating on the stock in a research report on Thursday, May 22nd. Robert W. Baird reduced their price objective on Apellis Pharmaceuticals from $55.00 to $47.00 and set an “outperform” rating on the stock in a research report on Thursday, May 8th. Needham & Company LLC reduced their price target on Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. raised their price target on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $18.30 on Friday. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $2.30 billion, a PE ratio of -9.01 and a beta of 0.68. The business’s 50-day moving average price is $18.31 and its 200-day moving average price is $25.03. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $43.15.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The firm had revenue of $149.90 million for the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.54) earnings per share. Sell-side analysts forecast that Apellis Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of APLS. Savant Capital LLC lifted its holdings in Apellis Pharmaceuticals by 42.5% in the 4th quarter. Savant Capital LLC now owns 31,525 shares of the company’s stock worth $1,006,000 after buying an additional 9,407 shares during the period. Banque Pictet & Cie SA lifted its stake in shares of Apellis Pharmaceuticals by 31.7% in the 4th quarter. Banque Pictet & Cie SA now owns 97,299 shares of the company’s stock valued at $3,105,000 after purchasing an additional 23,416 shares during the period. Ieq Capital LLC lifted its stake in shares of Apellis Pharmaceuticals by 1,425.5% in the 4th quarter. Ieq Capital LLC now owns 126,710 shares of the company’s stock valued at $4,043,000 after purchasing an additional 118,404 shares during the period. Handelsbanken Fonder AB lifted its stake in shares of Apellis Pharmaceuticals by 10.9% in the 4th quarter. Handelsbanken Fonder AB now owns 30,600 shares of the company’s stock valued at $976,000 after purchasing an additional 3,000 shares during the period. Finally, Legacy Capital Group California Inc. purchased a new position in shares of Apellis Pharmaceuticals in the 4th quarter valued at approximately $230,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).